World News

The latest agreement aligns with Teva’s broader “Pivot to Growth” strategy, which focuses on strengthening its innovative medicines and biosimilars businesses through collaborations that expand its global pipeline.

The setback comes at a crucial time as competition intensifies in the fast-growing market for lower-cost versions of Novo Nordisk’s blockbuster diabetes and obesity medicine.

The agreement gives Apollo-managed funds and affiliates a non-controlling interest in a newly created entity that will hold Bayer’s LARC portfolio.

The investment will fund the construction of a new 500,000-square-foot manufacturing facility, along with extensive upgrades to the company’s existing 700,000-square-foot plant in Austin, Texas.

The approval allows laboratories across Europe and other CE-recognising markets to use the assay to support the clinical evaluation of amyloid pathology in people showing signs of cognitive decline.

Evonik will use the funding to upgrade major production assets, including large reactors and other critical processing systems.

Under the agreement, researchers will gain access to an integrated platform that combines Evogene’s AI-powered computational chemistry engine, ChemPass AI, with the BCDD’s laboratory infrastructure and drug discovery expertise.

Philips developed Alturion to simplify routine ultrasound examinations without compromising image quality.

The Nottingham site also supports Codis’ commercial spray-drying operations in Haverhill, U.K., where the company is increasing capacity by installing a new GEA Pharma-SD PSD-4 commercial spray dryer, with validation planned for 2027.

Researchers will use GE HealthCare’s StarGuide SPECT/CT imaging system together with MIM Software’s MIM LesionID Pro platform to monitor how tumours respond throughout treatment.